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01. Introduction 
The U.S. Advisory Committee on Immunization Practices (ACIP) provides expert external advice 
and guidance to the Director of the Centers for Disease Control and Prevention (CDC) and the 
Secretary of the Department of Health and Human Services (HHS) on use of vaccines and related 
agents for control of vaccine-preventable disease in the U.S. civilian population. Information on 
the charter, structure, role, procedures, and membership of the ACIP are available at 
http://www.cdc.gov/vaccines/acip/committee/index.html. Resources and tools for implementing 
3 
 
ACIP recommendations are available at http://www.cdc.gov/vaccines/.   
The ACIP unanimously voted during its October 2010 meeting to adopt the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach for developing 
evidence-based recommendations. The purpose of this handbook is to provide guidance to the 
ACIP workgroups on using the GRADE approach for assessing the type or quality of evidence and 
for using that evidence to inform recommendations. Key factors for developing 
recommendations include the balance of benefits and harms, type or quality of evidence, values 
and preferences, and health economic analyses.  
The ACIP recommendation categories are – 
· Category A: Recommendation that applies to all persons in an age- or risk-based group. 
· Category B: Recommendation for individual clinical decision making. 
· No recommendation/unresolved issue. 
Category A recommendations will be made for all persons in an age group or for all persons in a 
risk-based group. The suggested phrasing for category A recommendations include the words 
recommend, recommend against, should, and should not. Category B recommendations will 
indicate that clinical decisions should be made on an individual basis, i.e., category B 
recommendations do not apply to all members of a group, but are used in context of clinician-
patient interaction to determine if vaccination may be appropriate for that patient. Phrasing for 
category B recommendations includes the words may, and suggest against. In some instances, it 
is possible that the ACIP may decide not to make a recommendation if additional information is 
needed.  
The body of evidence is to be categorized into four types that represent a general hierarchy 
reflecting the confidence in the estimated effect of vaccination on health outcomes (benefits, 
harms):  
1. Randomized controlled trials, or overwhelming evidence from observational studies. 
2. Randomized controlled trials with important limitations, or exceptionally strong evidence 
from observational studies. 
3. Observational studies, or randomized controlled trials with notable limitations. 
4. Clinical experience and observations, observational studies with important limitations, or 
randomized controlled trials with several major limitations.   
The process for evaluating a body of evidence and moving from evidence to recommendations 
includes the following steps: 
· Formulating specific questions to be answered by a recommendation. 
· Identifying all important outcomes for every question (benefits, harms). 
· Judging the relative importance of outcomes. 
· Summarizing all relevant evidence for important outcomes. 
· Categorizing the type or quality of evidence for each outcome. 
· Categorizing the overall type of evidence across outcomes. 
· Assessing health economic data. 
· Assessing the underlying values related to the management options and outcomes. 
· Judging the balance of desirable and undesirable effects. 
· Deciding on the recommendation category. 
· Formulating a recommendation. 
02. Formulating Questions  
The GRADE system is intended to be applied to questions about alternate intervention strategies 
(e.g. vaccination vs. no vaccination). It is not intended to be applied to background questions or 
“good practice recommendations” where the recommendation is not actionable or the 
alternative is not credible or is a violation of basic standards of care (e.g. definition of influenza-
like illness; use of antiseptic techniques for vaccination). 
The scope of each recommendation should be defined, with each recommendation answering a 
focused healthcare question. Each question should indicate the Population, Intervention, 
Comparison, and Outcomes (PICO) of interest. The questions are the starting point for 
formulating recommendations, and will drive the research direction (inclusion and exclusion 
criteria for the literature search) and determine the types of information that will be both 
searched for and assessed. 
03. Choosing and Ranking Outcomes 
Important outcomes that need to be considered in making a recommendation need to be 
identified. The purpose is to identify the outcomes that will be important or critical for making 
recommendations, and to identify the data that should be sought through evidence retrieval and 
synthesis. The outcomes are to be selected based on what is important, not what was measured 
in studies. An important outcome for which evidence is lacking should not be ignored and 
excluded from the evidence tables; the lack of evidence may influence the ultimate 
recommendation. 
Surrogate outcomes should be considered only when evidence about health outcomes is lacking. 
When this is the case, both the health outcomes and the associated surrogates that must be 
used as substitutes should be specified. The surrogate themselves (e.g. immunogenicity) should 
not be listed as the measures of outcome.  
4 
 
ACIP workgroup members should make an initial list of possibly relevant outcomes, including 
both desirable and undesirable effects. Each member should be asked to score the importance of 
each outcome on a 1 to 9 scale using a modified Delphi process, where 7–9 indicates that the 
outcome is critical for a decision, 4–6 indicates that it is important but not critical, and 1–3 
indicates that it is of limited importance. Guidance on using the modified Delphi process to rate 
importance is provided in The RAND/UCLA Appropriateness Method User’s Manual, chapters 6–8 
(available from http://www.rand.org/pubs/monograph_reports/MR1269.html). If a surrogate 
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outcome is used, the importance of the corresponding health outcome rather than that of the 
surrogate outcome should be scored. The average score for each outcome can be used to 
determine its relative importance, though it is helpful to provide the range of results as well.  
The importance of health outcomes is likely to vary within and across cultures or when 
considered from the perspective of the general population, patients, clinicians, or policy-makers. 
Workgroup members should decide what perspective they are taking. The perspective might vary 
by type of outcome (e.g. benefits, harms, cost-effectiveness).   
The importance of health outcomes should be ranked before the evidence is reviewed to focus 
the evidence search and to clarify or resolve disagreements. However, after the evidence review, 
the ranking should be reassessed in light of the evidence review. It is possible that in some 
instances the importance of an outcome may only become known after the evidence has been 
reviewed. For instance:  
· An outcome pertaining to a benefit may have been judged initially to be critical for 
making a recommendation, but it may no longer be considered to be critical if other 
benefits are evident; or 
· A suspected adverse event may be initially considered to be critical, but if the evidence 
review shows that the adverse event is not causally associated with the intervention, it 
may be considered important but not critical.  
Outcomes that are important or critical to decision making should be included in evidence tables 
whether or not information about them is available. Only outcomes considered critical are the 
primary factors influencing a recommendation and should be used to determine the overall 
evidence type supporting a recommendation. 
04. Evidence Retrieval 
A summary of all relevant research evidence is essential when developing a recommendation. 
Evidence should be sought relating to all important and critical outcomes. The most important 
type of evidence is that concerning the effect of interventions being considered in the 
recommendation. A recommendation should be based on the best available evidence related to 
the question that has been formulated.  
If the body of evidence from randomized controlled trials (RCTs) for a question is rated as 
evidence type 1 (the highest level of evidence), it may not be necessary to evaluate observational 
studies. However, if evidence from RCTs is downgraded to evidence type 2, 3, or 4, evidence 
from observational studies may provide complementary information that may prevent such a 
downgrade, or observational studies might provide a higher evidence level than RCTs. 
Systematic methods should be used to identify the evidence. In contrast to narrative reviews, 
systematic methods address a specific question and apply a rigorous scientific approach to the 
selection, appraisal and synthesis of relevant studies. A systematic approach requires 
documentation of the search strategy used to identify all relevant published and unpublished 
studies and the eligibility criteria for the selection of studies. Systematic methods reduce the risk 
of selective citation and improve the reliability and accuracy of decisions. The Cochrane 
handbook provides guidance on searching for studies, including grey literature and unpublished 
studies (Chapter 6, Section 6.2, available at http://handbook.cochrane.org/). 
An expert librarian should be consulted prior to conducting a search. He or she can help 
formulate a strategy that includes specific search terms and can assist in searches. This strategy 
should be documented and should specify: 
· The details of the databases to be searched, and the search strategy to be applied to each 
database, e.g. PubMed; EMBASE; Cochrane Central Register of Controlled Trials 
(CENTRAL); databases of systematic reviews (Cochrane Library, etc.); databases of 
guidelines (US National Guideline Clearinghouse, etc.).  
· The details of each strategy as actually performed, with search terms (key words and/or 
MESH terms), the date(s) on which the search was conducted and/or updated, and the 
publication dates of the literature covered. 
Searches should be supplemented by reviewing references in the included studies and reviews, 
examining clinical trials registries maintained by the federal government (www.clinicaltrials.gov) 
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and vaccine manufacturers, and consulting subject matter experts.  
The criteria for including/excluding evidence identified by the search, and the reasons for 
including and excluding evidence, should be described (e.g. population characteristics, 
intervention, comparison, outcomes, study design, setting, language).  The PRISMA Statement 
(www.prisma-statement.org) and AMSTAR instrument (http://amstar.ca/) include guidance on 
reporting the methods for evidence retrieval. 
05. Type or Quality of Evidence 
The evidence is to be assessed separately for each outcome. The body of evidence (not individual 
studies) is to be categorized into four types: 
1) Randomized controlled trials, or overwhelming evidence from observational studies; 
2) Randomized controlled trials with important limitations, or exceptionally strong evidence 
from observational studies; 
3) Observational studies, or randomized controlled trials with notable limitations; 
4) Clinical experience and observations, observational studies with important limitations, or 
randomized controlled trials with several major limitations.   
The above evidence categories represent a general hierarchy that reflect confidence in the 
estimated effect of an intervention on health outcomes. Randomization reduces potential bias 
and confounding, and randomized controlled trials are considered the gold standard for 
assessing vaccine efficacy. However, observational studies may provide more relevant 
information than randomized trials in certain situations (e.g. to assess rare adverse events).  
06. GRADE Criteria Determining Type or Quality of Evidence 
The GRADE approach for assessing the type or quality of evidence involves consideration of 
several criteria in addition to the traditional assessment of risk of bias (i.e. study limitations), as 
shown in the Table below. 
Table. GRADE criteria for assessing type or quality of evidence 
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1 Risk of bias 
-1  Serious  
-2  Very serious  
 
Inconsistency 
-1  Serious  
-2  Very serious  
 
Indirectness 
-1  Serious  
-2  Very serious  
Imprecision 
-1  Serious  
-2  Very serious  
Publication bias 
-1  Likely  
-2  Very likely  
Strength of association 
+ 1  Large  
+ 2  Very large  
 
Dose response 
+ 1  Evidence of a gradient 
 
Opposing plausible residual 
confounding or bias 
+ 1  Would reduce a 
demonstrated effect, or  
+ 1  Would suggest an  effect 










1 = Randomized controlled trials (RCTs), or overwhelming evidence from observational studies. 
2 = RCTs with important limitations, or exceptionally strong evidence from observational studies. 
3 = Observational studies, or RCTs with notable limitations. 
4 = Clinical experience and observations, observational studies with important limitations, or RCTs 
with several major limitations.  
bOccasionally, other considerations that do not fit into the three criteria listed here may raise confidence 
in the findings and therefore warrant upgrading the evidence type. 
Assessing the type or quality of the body of evidence for each outcome begins with the study 
design. Studies are classified into two types: 
· Randomized controlled trials (RCTs); 
· Observational studies. Examples include cohort studies, case-control studies, controlled 
before-after studies, interrupted time series studies, case series, case reports.  
The PICO question needs to be taken into consideration when determining the classification of a 
study. For example, a study in which infants are randomized into two different vaccination 
schedules would be classified as an RCT if the question concerns which vaccination schedule is 
more effective, but it would be classified as an observational study with no control group if the 
comparison group of interest is infants who do not receive vaccination.  
RCTs are initially classified as evidence type 1, and observational studies as evidence type 3. Five 
GRADE criteria are used for downgrading the evidence type: risk of bias; inconsistency; 
indirectness; imprecision; and publication bias. Three GRADE criteria are primarily used to 
upgrade the evidence type: strength of association; dose-response; and opposing plausible 
residual confounding or bias.   
The GRADE criteria for upgrading or downgrading the evidence level may be additive. For 
example, when well-performed observational studies demonstrate both strength of association 
and dose-response, the evidence type may be upgraded by two levels to 1. Reviewers should 
categorize the final evidence type by considering an individual GRADE criterion in the context of 
strengths or limitations identified in any of the other GRADE criteria. For example, if limitations 
pertaining to the risk of bias and indirectness criteria are identified, but these limitations are not 
serious enough for moving down each of them, the evidence type may be downgraded by one 
level when limitations for both criteria are considered together. The GRADE criterion that played 
the biggest role in downgrading as well as all contributing factors should be specified. 
07. Criteria for Downgrading Evidence Level 
There are five GRADE criteria for assessing limitations that can lower the evidence level for 
randomized trials and observational studies: risk of bias; inconsistency; indirectness; imprecision; 
and publication bias. 
7.1 .   Risk of Bias (Study Limitations) 
Study limitations may bias the estimates of the effect of an intervention on health outcomes. The 
assessment of risk of bias should apply to studies contributing to results in the evidence tables, 
rather than to all studies that could potentially be included in the analysis. The criteria for 
evaluating study limitations or risk of bias (also referred to as internal validity) will depend on the 
study design. The number of studies is not a determining factor in determining risk of bias; a 
single well-conducted multicenter RCT may result in high confidence in the estimated effect of 
vaccination on health outcomes. 
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Randomized Control Trials 
For RCTs, criteria established by the Cochrane Collaboration include: allocation sequence 
generation (selection bias); allocation sequence concealment (selection bias); blinding of 
participants and personnel (performance bias); blinding of outcome assessment (detection bias); 
incomplete outcome data (attrition bias); and selective outcome reporting (reporting bias) (ref: 
Cochrane handbook, Chapter 8, Section 8.5, http://www.cochrane-handbook.org/). Studies 
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where study participants are allocated to intervention or control arms through quasi-
randomization techniques (e.g. allocation by odd or even date of birth, date or day of admission, 
case record number, alternation/rotation) will automatically be downgraded because of risk of 
selection bias due to inadequate generation of a randomized sequence and ability of participants 
or investigators enrolling participants to foresee allocation. Blinding of outcome assessors is less 
important for the assessment of objective outcomes such as all-cause mortality, but crucial for 
subjective outcomes. Risk of bias can differ across outcomes (e.g. higher risk of bias for 
subjective outcomes compared to objective outcomes when outcome assessors are not blinded; 
different subsets of studies for safety vs. efficacy studies). For adverse events or non-inferiority 
studies, intention-to-treat analyses may not be appropriate (ref: Cochrane handbook, Chapter 
16, Section 16.2.1). If any information needed for assessing risk of bias is not reported in a 
publication, one option is to contact study investigators. It may sometimes be possible to assess 
risk of bias from other reported information. For example, if information on allocation sequence 
concealment is not reported, data showing that the intervention and control groups are balanced 
at baseline may assuage concern regarding risk of bias. Assessing risk of bias due to incomplete 
outcome data involves considering the reasons for the missing data as well as the numbers 
missing (ref: Cochrane handbook, Chapter 8, Section 8.13). A relatively simple method for 
assessing the effect of missing data on risk of bias, which involves making plausible assumptions 
about the outcomes of persons with missing data, is described in the following articles:  
· Akl EA, Johnston BC, Alonso-Coello P, et al. Addressing dichotomous data for participants 
excluded from trials: a guide for systematic reviewers. PLoS One, 2013;8(2):e57132. 
· Ebrahim S, Akl EA, Mustafa RA, et al. Addressing continuous data for participants 
excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical 
Epidemiology, 2013 Sep;66(9):1014-21. 
For cluster RCTs, the Cochrane Collaboration’s criteria for assessing risk of bias include 
assessment of the following: recruitment bias; baseline imbalance; loss of clusters; failure to 
account for clustering in the analysis; and comparability with individually randomized trials (ref: 
Cochrane handbook, Chapter 16, Section 16.3). 
Observational Studies 
Observational studies include cohort; case-control; controlled before-after; interrupted time 
series; case series; and case reports. For cohort and case-control studies, domains for evaluating 
risk of bias include: selection of the study groups; comparability of the groups; and 
ascertainment of either the outcome or exposure for cohort and case-control studies, 
respectively (ref: Newcastle-Ottawa Scale, 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm). For interrupted time series 
(e.g. population-based surveillance studies with multiple data points before and after 
introduction of vaccination) and controlled before-after studies, evaluation criteria developed by 
the Cochrane Effective Practice and Organization of Care Group can be used (ref: EPOC Reviewer 
Tools, http://epoc.cochrane.org/epoc-author-resources). Case series and case reports are 
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observational studies that investigate only persons exposed to the intervention. Source of 
control group results is implicit or unclear, thus, they will usually warrant classification as 
observational studies with important limitations. An explicit control group, however, may not 
always be necessary. For example, if vaccination of a large number of representative persons 
shows high seroconversion rates (referred to as case series or single group cohort study) AND if 
seroconversion rates in unvaccinated persons would be expected to be near zero, the absence of 
a concurrent control group may not be considered to be an important limitation. In a similar 
vein, if post-marketing phase 4 studies of a very large number of vaccine recipients show that the 
incidence of an adverse event is rare, and if one were confident that all events were detected, 
one would have high confidence that even if there were an association, the magnitude of 
absolute risk would be very small.  The absolute risk of an adverse event may be more relevant 
for patients and populations than the relative risk. 
Considerations on Study Limitations 
Reviewers should consider the extent to which study limitations may bias the results. The risk of 
bias for each outcome is to be assessed using the following categories: 
· No serious limitations (do not downgrade evidence type): most of the studies comprising 
the body of evidence have low risk of bias for all key criteria for evaluating study 
limitations.  
· Serious limitations (downgrade one level): most of the studies have crucial limitation for 
one criterion or some limitations for multiple criteria that lower confidence in the 
estimated effect of vaccination on the outcome of interest.   
· Very serious limitations (downgrade two levels): most of the studies have crucial 
limitation for one or more criteria that substantially lower confidence in the estimated 
effect. 
When considering a body of evidence in which some studies have no serious limitations, some 
have serious limitations, and some have very serious limitations, it is not appropriate to 
automatically assign an average rating of serious limitations for the group of studies. When the 
risk of bias varies across studies, principles for determining whether to downgrade the evidence 
type for a group of studies include: 
· Consider the extent to which each study contributes to the overall or pooled estimate of 
effect. Larger studies with many outcome events will contribute more;  
· Assess whether the results differ for studies with low risk of bias and those with high risk 
of bias and consider focusing on studies with lower risk of bias if the results differ by risk 
of bias; 
· Downgrade when there is substantial risk of bias across most of the studies;  
· Consider limitations pertaining to the other GRADE criteria (if there are close calls 
regarding risk of bias with another GRADE criterion, consider downgrading the evidence 
level for at least one of the two GRADE criteria). 
  
When close-call situations occur, this should be made explicit, and the reason for the ultimate 
classification should be stated. 
7.2 .   Inconsistency 
Inconsistency refers to an unexplained heterogeneity in the magnitude of the effect size (e.g. 
relative risk or odds ratio for binary outcomes; mean difference for continuous outcomes) across 
studies. If only one study is available, the inconsistency criterion is not applicable. Inconsistency 
can be assessed using point estimates, overlap of confidence intervals, and statistical tests of 
heterogeneity and I2.  The following indicate inconsistency: 
· Point estimates vary widely across studies; 
· Confidence intervals do not overlap or show minimal overlap; 
· Statistical test for heterogeneity shows P-value of < 0.05;  
· I2 is large (I2 around 50% is moderate and >75% is considerable).  
Inconsistency in results may arise from differences in: 
· Populations (e.g. vaccines may have different relative effects in sicker populations); 
· Interventions (e.g. different effects with different number of doses or comparators); 
· Outcomes (e.g. duration of follow-up); 
· Study methods (e.g. studies with higher and lower risk of bias). 
When heterogeneity is large, but a plausible explanation can not be identified, the evidence level 
should be downgraded by one or two levels, depending on heterogeneity in the magnitude of 
effect. If inconsistency can be explained, estimates of effect should be presented separately for 
the stratification that explains the observed heterogeneity. If results differ by study methods, 
preference may be given to results of studies with a lower risk of bias. If results differ by 
population groups, different recommendations may be made for different groups. 
For binary outcomes, inconsistency should be assessed using risk ratio or odds ratio. Risk 
difference should not be used to assess inconsistency, as risk difference is very sensitive to the 
baseline risk (i.e. risk in control group) and baseline risk can differ substantially between studies. 
The forest plot below shows three studies with consistent risk ratios for a binary outcome: point 
estimates are compatible across the studies; confidence intervals overlap; P-value for 




The forest plot below for a continuous outcome shows non-overlapping confidence intervals of 
the mean difference and a large I2, but the differences are between small and large beneficial 
effects. The evidence level may or may not be downgraded for inconsistency. The decision for 
downgrading would depend on factors such as whether the uncertainty about the magnitude of 
benefit would influence the overall judgment about net benefit across all outcomes.  
7.3 .   Indirectness 
Evidence can be indirect in the following situations:  
· The population that participated in studies may differ from the population of interest;   
· The intervention that was evaluated may differ from the intervention of interest; 
· The outcome that was assessed may differ from that of primary interest; 
· The primary interest is head-to-head comparisons of vaccine A to vaccine B, but A was 
compared with C and B was compared with C.   
Table. Examples of indirect evidence 
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Indirect Question of Interest Source of Indirectness 
Population Efficacy of vaccine in preventing 
disease in older persons with 
chronic health conditions 
Studies are available for healthy persons, but 
not for the population of interest 
Intervention Efficacy of a new formulation of 
a vaccine in preventing disease 
Studies of previous formulations of the 
vaccine provide indirect evidence bearing on 
the new vaccine 
Comparator Efficacy of  vaccine A compared 
to vaccine B in preventing 
disease 
Studies compared vaccine A to placebo and 
vaccine B to placebo, but studies comparing A 
to B are unavailable  
Outcome Prevention of disease Increase in antibody titers following 
vaccination are reported, but there are no 
well-established standard correlates of 
protection 
Indirectness can lower the evidence level by one or even two levels. To assess indirectness or 
applicability pertaining to the population, consider whether there are compelling reasons to 
think that differences in biological or social factors would result in substantial differences in the 
magnitude of the relative effect as opposed to differences in absolute effects that are influenced 
by differences in the baseline incidence of disease across population groups. Because many 
interventions have similar relative effects across most population groups, assessment of 
directness across population groups should not be excessively stringent. On the other hand, 
studies using surrogate outcomes generally provide less direct evidence than those using health 
outcomes. Immunogenicity is a surrogate for disease incidence that would result in lowering of 
the evidence level unless there are well-established standard correlates of protection. Because 
evidence levels reflect the level of confidence in the estimated effect of vaccination in reducing 
disease, considerations of the feasibility of obtaining direct evidence should not influence the 
decision to downgrade the evidence level due to indirectness.  
Complementary information from observational studies may be helpful to assess whether 
evidence from RCTs is direct enough. For example, evidence from RCTs conducted in men may 
not be downgraded when the population of interest includes both men and women if 
observational studies show that an intervention has the same effect in men and women. Further 
information on assessing indirectness is available in the following article: Schunemann HJ, 
Tugwell P, Reeves BC, et al. Non-randomized studies as a source of complementary, sequential or 
replacement evidence for randomized controlled trials in systematic reviews on the effects of 
interventions. Research Synthesis Methods 2013;4:49-62. 
7.4 .   Imprecision 
Imprecision refers to studies having relatively few participants and few events that result in wide 
confidence intervals around the effect size.  
For systematic reviews, the following indicate imprecision for an outcome: 
· Total sample size across all studies for an outcome is lower than the calculated sample 
size for a single adequately powered study (online calculators are available for sample 
size calculations, e.g. http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html); or  
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· 95% confidence interval (CI) of the pooled or best estimate of effect size includes both no 
effect AND appreciable benefit or appreciable harm (even if sample size is adequate). For 
binary outcomes, the suggested threshold for appreciable benefit or appreciable harm 
that should be considered for downgrading is a relative risk of 0.75 or 1.25, respectively 
(i.e. relative risk reduction or relative risk increase greater than 25%). For example, a 
relative risk with a 95% CI of 0.90 to 1.20 would be considered to be precise (1.20 is 
below the threshold of 1.25), whereas a relative risk with a 95% CI of 0.90 to 1.30 would 
be considered to be imprecise (1.30 is above the threshold of 1.25). When an outcome is 
rare, 95% CIs of relative effects may be very wide but 95% CIs of absolute effects may be 
narrow; in such situations, the evidence level may not be downgraded. For continuous 
outcomes, the threshold for appreciable benefit or appreciable harm refers to the 
difference in score in the outcome that are perceived as important. 
For developing a guideline or recommendation, additional consideration should be given to 
whether the evidence is adequate to support a particular recommendation taking into account 
all outcomes together. The evidence level may be downgraded because of imprecision in the 
following situations: 
· When the recommendation is for an intervention and 
o the 95% CI includes both no effect AND an effect that represent a benefit that 
would outweigh potential harms 
o the 95% CI excludes no effect but the lower confidence limit crosses a threshold 
below which, given potential harms, one would not recommend the intervention 
· When the recommendation is against an intervention and 
o the 95% CI includes no effect AND an effect that represent a harm that, despite 
the benefits, would still be unacceptable 
o the 95% CI excludes no effect but the upper confidence limit crosses a threshold 
above which, given the benefits, one would recommend the intervention. 
It should be noted that concerns about imprecision in evidence from RCTs may be alleviated if 
complementary information from observational studies support the results of RCTs (ref: 
Schunemann et al. Research Synthesis Methods, 2013;4:49-62).     
More information on assessing imprecision is available in the following article:  Guyatt G, Oxman 
AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. J Clin 
Epidemiol 2011;64:1283-93. 
7.5 .   Publication Bias 
Publication bias is a systematic underestimate or an overestimate of the underlying beneficial or 
harmful effect due to the selective publication of studies. Publication bias arises when 
investigators fail to publish studies, typically those that show no effect. Publication bias should 
be suspected if the available studies are uniformly small and funded by industry. A funnel plot of 
studies, with magnitude of the effect size (e.g. relative risk or odds ratio for a binary outcome) on 
the x-axis and variance (proxy for sample size) on the y-axis, can help assess publication bias. A 
funnel plot with asymmetrical distribution suggests publication bias. 
08. Criteria for Upgrading Evidence Level 
There are three primary criteria for moving up the evidence level: strength of association; dose-
response gradient; and opposing plausible residual confounding or bias. On occasions, particular 
design features may warrant moving up the evidence level. For example, well-conducted 
observational studies showing that a vaccine reduces disease due to vaccine serotypes but not 
due to non-vaccine serotypes may increase confidence in the results if it is thought that the 
effect of possible biases because of unmeasured confounders would be similar for vaccine 
serotypes and non-vaccine serotypes.  
Observational studies that have been downgraded for any reason (risk of bias, imprecision, 
inconsistency, indirectness, or publication bias) should not be moved up using the criteria for 
upgrading. RCTs that have been downgraded should generally not be moved up, except under 
certain circumstances. RCTs that have been downgraded because of quasi-randomization (e.g. 
allocation by day of week) may be moved up. RCTs that have been downgraded because of 
indirectness may be moved up in some instances.    
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8.1. Strength of Association 
When methodologically strong observational studies show strong and consistent estimates of the 
magnitude of a treatment or exposure effect, one may be confident about the results. The 
stronger the association, the less likely it is that all of the apparent benefit or harm can be 
explained by residual confounding or bias, even though observational studies are likely to 
provide an overestimate of the true effect. The stronger the strength of association, the stronger 
becomes the evidence. The evidence level may be upgraded by one level if the relative risk from 
at least 2 studies is approximately >2 or <0.5, and it may be upgraded by two levels if the relative 
risk is approximately >5 or <0.2. For odds ratios, similar thresholds can be used for upgrading 
when the baseline risk is below 20%; when the baseline risk is higher, odds ratios do not 
approximate risk ratios, and higher thresholds for odds ratios may be appropriate. Both the point 
estimate and the confidence interval should be considered when upgrading; the evidence level 
should usually not be upgraded if the confidence interval overlaps substantially with the 




Association Effect Measurea Evidence Level 
Strong Relative Risk approximately >2 or <0.5 (based on 
consistent evidence from at least 2 studies) 
Move up 1 level 
Very strong Relative Risk approximately >5 or <0.2  Move up 2 levels 
aRelative risks of 0.5 and 0.2 correspond to vaccine efficacies of 50% and 80%, respectively. Vaccine 
efficacy = (1 – Relative Risk) x 100. 
































aIncluded cohort and case-control studies available at the time the ACIP withdrew its recommendation for 
use of Rotashield vaccine; excluded ecological studies. 
bUpgraded initial evidence type of 3 by two levels because relative risk of intussusception for vaccinated 
compared to unvaccinated infants is greater than 5 (strength of association). 
 
















































Yesc None 4 
aMMRV compared to separate injections of MMR and Varicella vaccination for children ages 12-23 
months. 
bUpgraded initial evidence type of 3 by one level because relative risk ~2 based on consistent evidence 
from two studies (strength of association).  
cDowngraded initial evidence type of 3 by one level because of imprecision. One study indicated a 
decrease but not significant, one study found no association (because the confidence intervals 
overlapped, the results were not considered to be heterogeneous). 
8.2. Opposing Plausible Residual Confounding or Bias 
All plausible residual confounding or bias may on occasion be working to reduce the 
demonstrated effect (or increase the effect if no effect was observed). For example, if a vaccine 
is suspected of being associated with an adverse event, and the publicity results in increased 
spontaneous reporting of the adverse event among vaccinated persons compared to that in 
unvaccinated persons, yet epidemiological studies find no association, the evidence level for the 
lack of association can be upgraded.   
8.3. Dose-response Gradient 
The presence of a dose-response gradient may increase confidence in the findings of 
observational studies and thereby increase the evidence level. Examples include greater vaccine 
efficacy with increasing number of doses, and declining disease with increasing population 
vaccination rates. 
09. Indirect Evidence 
Indirect evidence may help facilitate decision making. For example, for the development of the 
2011 ACIP recommendation for routine use of quadrivalent HPV vaccine in males, data on the 
efficacy of HPV vaccine in preventing anal intraepithelial neoplasia (AIN) 2/3 – a surrogate for 
anal cancer – were available for the MSM (men who have sex with men) population but not for 
the general population. The evidence type for the outcome anal cancer was downgraded by one 
level for indirectness because of the use of a surrogate, but it was not downgraded further for 
differences in population characteristics because there was no reason to suspect that the efficacy 
in preventing AIN 2/3 in the general population would differ from that observed in the MSM 
population. 
10. Overall Evidence Type 
The overall evidence type combines evidence across many outcomes considered critical for a 
recommendation. When the body of evidence for an outcome includes both RCTs and 
observational studies, the study design that provides higher evidence level should be selected for 
that outcome when determining the overall evidence type. The overall evidence type is generally 
the lowest evidence type of the critical outcomes. An exception to this guidance is when the 
evidence type differs across critical outcomes but the association is similar in direction. For 
example, if data from well-conducted RCTs (i.e. the highest level of evidence) show that a vaccine 
reduces incidence of disease and hospitalization, and data from ecological studies indicate 
protective effect due to herd immunity, the overall evidence type may be categorized as RCTs 
even if herd immunity is considered to be a critical outcome. 
11. Pooling Effect Estimates 
Summary effect estimates across studies can be generated using meta-analysis software, by 
either the fixed-effect model or the random-effects model. The fixed-effect model assumes that 
included studies are functionally identical. The random-effects model is appropriate if the true 
effect size could vary across studies because of functional differences in population, intervention, 
comparison, or outcome definitions that could have affected the results. The studies, however, 
should have enough in common for the pooled estimate to be meaningful. 
Summaries of binary outcomes (events, total) or continuous outcomes (mean, standard 
deviation, total) for each study group can be entered into a meta-analysis software such as 
RevMan (available at http://ims.cochrane.org/revman). It is also possible to enter effect 
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estimates and standard errors (or confidence intervals) directly into RevMan using the ‘Generic 
inverse variance’ method for the random-effects or fixed-effect model. The inverse variance 
method, for example, enables pooling of adjusted effect estimates (e.g. adjusted odds ratios) for 
observational studies (ref: Cochrane Handbook, Chapter 9, Section 9.4.3). 
Studies that used two independent groups, matched groups, and clustered groups may be 
included in the same meta-analysis. Effect size and variance for each study is computed, taking 
into consideration the study design. 
11.1   Binary Outcomes 
Meta-analysis should be conducted using relative measures of effect (e.g. relative risk, odds 
ratio). It should be noted that using pooled risk difference estimates from meta-analyses may be 
misleading, because risk difference is very sensitive to the baseline risk, and baseline risk can 
differ substantially between studies. However, when baseline risk is very low, confidence 
intervals computed from meta-analysis of relative measures of effect may be misleading, and 
direct computation of pooled risk difference using meta-analysis is preferable.  
An example of a forest plot showing pooled relative risk and 95% confidence intervals (CIs) 
generated using RevMan software is shown below: 
GRADEPro software can be used to generate risk difference estimates along with the confidence 
intervals for a range of baseline risks (see Appendix 3). Data on assumed incidence in controls 
and point estimate and 95% confidence interval of the pooled relative risk need to be entered 
into GRADEPro (or can be directly imported from RevMan) to generate the output. The assumed 
incidence in controls can be estimated from the control arms of studies (e.g. median incidence) 
or from other studies (e.g. surveillance studies). For example, if RCTs have assessed the 
effectiveness of an intervention in a population that differs from the population of interest, 
baseline risks in the population of interest derived from observational studies may be entered 
into GRADEPro to compute risk difference estimates. The formulae for computing risk differences 
or Number Needed to Treat (NNT) from the results of meta-analyses of risk ratios or odds ratios 
are given in the Cochrane handbook, Chapter 12, Section 12.5.4. The Cochrane handbook 
provides formulae for converting odds ratios to risk ratios (Chapter 12, Section 12.5.4.4). 
Additional information is available in the following article: Guyatt GH, Oxman AD, Santesso N, et 
al. GRADE guidelines 12. Preparing Summary of Findings tables – binary outcomes. J Clin 
Epidemiol. 2012;66(2):158-72. 
11.2   Continuous Outcomes 
For continuous outcomes, raw mean difference, standardized mean difference, or response ratio 
can be computed. Raw mean difference is appropriate if the measurement scale is intuitively 
meaningful (e.g. duration of diarrhea). If the measurement scale is not intuitively meaningful or if 
different studies use different scales for measuring an outcome, standardized mean difference 
should be used. Standardizing the mean difference in each study by dividing by the study’s 
standard deviation results in an outcome measure that is comparable across studies.  
An example of a forest plot using studies cited in a systematic review by Li et al (PLoS Medicine, 
2007) on Loperamide therapy for acute diarrhea in children for the outcome duration of diarrhea 
in days is shown below. The mean, standard deviation (SD), and sample size for the outcome in 
the Loperamide and control groups for each study were entered into RevMan. The pooled raw 
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mean difference is 0.55 days lower in the Loperamide group compared to the control group (95% 
CI: 0.95 days lower to 0.16 days lower).  
In situations where an outcome is reported as continuous data in some studies and as binary 
data in other studies, methods for combining continuous and binary data are provided in the 
Cochrane handbook, Chapter 9, Section 9.4.6. 
11.3  Geometric Mean Titers (Skewed Continuous Outcome)  
For geometric mean titers (GMTs), the data for each study need to be converted to a log scale for 
computing pooled estimates. The pooled results are then converted back into the original metric 
by taking their exponentials (anti-logs).  
An example of an immunogenicity meta-analysis using published randomized trials cited in a 
systematic review by Banzhoff et al (Gerontology 2003;49:177-84) is shown below. Standard 
deviations (SDs) have been derived from the reported 95% confidence intervals (CIs); for studies 
for which CIs were not reported, SDs have been imputed (ref: Cochrane handbook, Chapter 7, 
Section 7.7.3.2).  




Adjuvanted vaccine Non-adjuvanted vaccine 
n GMT (95% CI) n GMT (95% CI) 
Donato 1999 94 137 (115, 162) 98 84 (71, 99) 
Gasparini 2001 192 102 (92, 114) 99 70 (59, 83) 
Baldo 2001 99 75.6 (58.4, 92.9) 93 66.4 (54.9, 77.9) 
Martin 1997 277 111 186 76 
Menegon 1999 96 54.5 98 49.0 
Minutello 1999 46 115 46 74 
a95% CIs were not reported for the Martin, Menegon, and Minutello studies. 




Adjuvanted vaccine Non-adjuvanted vaccine 
n Loge GMT (Loge 95% CI) n Loge GMT (Loge 95% CI) 
Donato 1999 94 4.92 (4.74, 5.09) 98 4.43 (4.26, 4.60) 
Gasparini 2001 192 4.62 (4.52, 4.74) 99 4.25 (4.08, 4.42) 
Baldo 2001 99 4.33 (4.07, 4.53) 93 4.20 (4.01, 4.36) 
Martin 1997 277 4.71 186 4.33 
Menegon 1999 96 4.00 98 3.89 
Minutello 1999 46 4.74 46 4.30 
Table. Post-immunization GMT: Standard Deviations derived from 95% confidence intervalsa 
Study 
Adjuvanted vaccine Non-adjuvanted vaccine 
n Loge GMT (Loge SD) n Loge GMT (Loge SD) 
Donato 1999 94 4.92 (0.8365) 98 4.43 (0.8291) 
Gasparini 2001 192 4.62 (0.7531) 99 4.25 (0.8556) 
Baldo 2001 99 4.33 (1.1637) 93 4.20 (0.8495) 
Martin 1997 277 4.71 (0.8447)b 186 4.33 (0.8447) b 
Menegon 1999 96 4.00 (0.8447) b 98 3.89 (0.8447) b 
Minutello 1999 46 4.74 (0.8447) b 46 4.30 (0.8447) b 
aStandard deviation = Standard error x Square root of n; where Standard error = (Upper confidence limit – 
Lower confidence limit) ÷ t value. [t value for a 95% confidence interval can be obtained by typing =tinv(1-
0.95,n-1) in Excel, where n represents sample size)]. The Calculator in RevMan can be used to derive 
standard deviations from 95% confidence intervals.  
bLoge SD was imputed by using the average loge SD of non-adjuvanted vaccines from the Donato, 
Gasparini, and Baldo studies. 
Figure. Forest plot of post-immunization log-transformed GMT data 
Pooled GMT Ratio, adjuvanted vaccine vs. non-adjuvanted vaccine = e0.33 = 1.39 
95% CI of pooled GMT Ratio = e0.21, e0.44 = 1.23, 1.55 
Note: A sensitivity analysis where the extreme case loge SD of 1.1637 was imputed instead of the 
average loge SD resulted in a pooled GMT Ratio of 1.40 (95% CI: 1.25, 1.57). 
12. Evidence Tables 
The number of studies and participants, relative and absolute effects, and type or quality of 
evidence should be presented in tabular format to inform the development of 
recommendations. Each judgment pertaining to categorizing the evidence should be made 
explicit in order to increase the transparency of the process. Evidence tables should include 
footnotes explaining the reasons for upgrading or downgrading the evidence level.  
Data on benefits and harms should be summarized across studies so that evidence tables have 
one row for each outcome. If there are both randomized trials and observational studies for a 
given outcome, the quality of evidence for each type of design should be presented.  
Examples of evidence tables are provided in Appendix 1 (pages 36-38) and in the following 
article: Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L. Effect of influenza 
vaccination of health care personnel on morbidity and mortality among patients: Systematic 
review and grading of evidence. Clinical Infectious Diseases 2013; doi: 10.1093/cid/cit580. 
13. Health Economic Analyses 
Health economic evaluations take into account costs and health outcomes of an intervention in 
relation to its comparator. Effectiveness measures can be natural units (e.g. disease episodes or 
deaths prevented), quality-adjusted life years (QALYs), or can be expressed in monetary terms. 
Health economic analyses often use modelling in order to combine evidence from different 
sources and to extrapolate from the limited time-horizons of existing studies on health 
outcomes. The methodology described above for categorizing the type of evidence is not 
intended to be applied to health economic analyses based on modelling. Presentation of health 
economic data should be undertaken using the guidelines in the document titled Guidance for 




14. Values and Preferences 
Values and preferences can be described as the relative importance of outcomes related to 
benefits, harms, and costs. Ethical considerations can be considered under the rubric of values 
and preferences.  
There will always be advantages and disadvantages of alternative management strategies, and 
individuals will always have to make a trade-off between them. Therefore, the way a workgroup 
values particular benefits and risks can be decisive to any recommendation. The values used in 
making recommendations should reflect those of the people affected (e.g. general population, 
patients, clinicians, policy-makers).  While it is ideal to obtain values and preference estimates 
from representative population-based studies, such studies may not be available. If there is a 
paucity of published information on values, values of workgroup members may be used as a 
proxy. The ranked outcomes (see Section 03: Choosing and Ranking Outcomes) provide an 
indication of values of workgroup members.  
Methods for assessing values and preferences include discrete choice experiment, standard 
gamble, time trade off, and willingness to pay.  Examples of articles on values and preferences 
include: 
· Kuppermann M, Nease RF, Ackerson LM, Black SB, Shinefield HR, Lieu TA. Parents’ 
preferences for outcomes associated with childhood vaccinations. Pediatr Infect Dis J 
2000;19:129-33. 
· Gidengil C, Lieu TA, Payne K, Rusinak D, Messonnier M, Prosser LA. Parental and societal 
values for the risks and benefits of childhood combination vaccines. Vaccine 
2012;30:3445-52. 
· Prosser LA, Ray T, O’Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness 
to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 
2004;113(2):283-90. 
· Prosser LA, Payne K, Rusinak D, Shi P, Uyeki T, Messonnier M. Valuing health across the 
lifespan: Health state preferences for seasonal influenza illnesses in patients of different 
ages. Value in Health;2011;14:135-43. 
· Prosser LA, Bridges CB, Uyeki TM, et al. Values for preventing influenza-related morbidity 
and vaccine adverse events in children. Health and Quality of Life Outcomes 2005;3:18. 
http://www.hqlo.com/content/3/1/18. 
· Lavelle TA, Meltzer M, Gebremariam A, Lamarand K, Fiore AE, Prosser LA. Community-
based values for 2009 Pandemic Influenza A H1N1 illnesses and vaccination-related 
adverse events. PLOS ONE 6(12):e27777. 
· de Bekker-Grob EW, Hofman R, Donkers B, et al. Girls’ preferences for HPV vaccination: A 
discrete choice experiment. Vaccine 2010;28:6692-7. 
· Brown DS, Johnson FR, Poulos C, Messonnier ML. Mothers’ preferences and willingness to 
pay for vaccinating daughters against human papillomavirus. Vaccine 2010;28:1702-8. 
· Lieu TA, Ortega-Sanchez I, Ray T, et al. Community and patient values for preventing 
herpes zoster. Pharmacoeconomics 2008;26(3):235-49. 
· Lee GM, Salomon JA, Gay C, Hammitt JK. Preferences for health outcomes associated with 




· Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods 
for valuing short-term health states. Health and Quality of Life Outcomes 2005;3:17. 
http://www.hqlo.com/content/3/1/17. 
· Kramer MS, MacLellan A, Ciampi A, Etezadi-Amoli J, Leduc DG. Parents’ vs physicians’ 
utilities (values) for clinical outcomes in potentially bacteremic children. J Clin Epidemiol 
1990;43(12):1319-25. 
· Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult 
bacteremia. Arch Pediatr Adoles Med 2000;154:43-8. 
· O’Meara JJ, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of 
streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N 
Engl J Med 1994;330:1864-9. 
15. Balance of Desirable and Undesirable Effects 
Assessing the balance of benefits and harms for formulating recommendations involves 
considering the following factors: 
· Relative importance of outcomes (i.e. relative values that patients and other stakeholders 
place on benefits and harms); 
· Baseline risks of outcomes (i.e. incidence of outcomes in the absence of vaccination); 
· Magnitude of relative risk; 
· Magnitude of risk difference; 
· Precision (i.e. 95% confidence interval) of relative risk and risk difference estimates. 
The considerations for assessing the balance of desirable and undesirable effects include: point 
estimates of the effects of vaccination on all important and critical outcomes (e.g. relative risk, 
risk difference, NNT); and values and relative preferences attributed to these outcomes. Baseline 
risk of disease plays a role in determining the balance, since risk difference (and NNT) is a 
function of baseline risk and relative risk.  In general, the higher the baseline risk, the greater is 
the magnitude of benefit. 
16. Baseline Risk Estimates 
The GRADE criteria for assessing the type or quality of evidence regarding the effect of an 
intervention (risk of bias, indirectness, imprecision, inconsistency, publication bias) may be useful 
for assessing the quality of evidence of baseline risks of outcomes (ref: Spencer FA et al. BMJ 
2012;345:e7401, http://www.bmj.com/content/345/bmj.e7401). However, grading baseline 
risks may make the systematic review process overwhelmingly complex. Presenting the effect of 
a plausible range of baseline risk estimates on risk difference estimates may be sufficient to 
address possible concerns regarding the quality of baseline risk estimates. However, if necessary, 
uncertainty about baseline risk estimates can be classified under “indirectness” for assessing the 
quality of evidence regarding the effect of an intervention. 
17. Formulating Recommendations  
17.1   Recommendations Categories 
Category A recommendations apply to all persons in an age group (e.g. routine recommendation) 
or to all persons in a specified risk group. Category B recommendations do not apply to 
everyone, but in the context of a clinician-patient interaction, vaccination may be found to be 
appropriate for a person. In some instances, the ACIP may decide not to make a 
recommendation if additional information is needed.  
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17.2   Factors Determining the Recommendation Category 
The recommendation category reflects the balance between the desirable effects of adherence 
to the recommendation (benefits, savings) and the undesirable effects (harms, costs). The 
following table provides a brief explanation of the key factors for developing recommendations. 
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The larger the difference between the benefits and harms, the more likely is 
a category A recommendation warranted. The smaller the net benefit and 
the lower certainty for that benefit, the more likely is a category B 
recommendation warranted. 




The greater the variability in values and preferences, or uncertainty in values 




The lower the cost-effectiveness of vaccination, the less likely is a category A 
recommendation warranted. 
A category A recommendation is one for which the desirable effects clearly outweigh the 
undesirable effects (recommendation for) or that the undesirable effects clearly outweigh the 
desirable effects (recommendation against).  
A hypothetical example of key factors that can result in a category A recommendation is: 
Key Factors Comments 
Balance between 
benefits and harms 
There is considerable benefit and little expected harm. 
Benefits are valued much higher than expected minor harms. 
Evidence type 2 
Values and 
preferences 
Not a lot of variability in values and preferences in the target population. 
Health economic 
analyses 
Cost-effectiveness is high. 
Key factors that can lead to category B recommendations include:  
· Small benefits (e.g. small relative or absolute effects, low baseline risk); 
· Lower confidence in the estimated effect of vaccination on health outcomes (e.g. studies 
with major limitations); 
· Variation or uncertainty in how different individuals value the outcomes; 
· Lower cost-effectiveness or lack of adequate data on cost-effectiveness. 
The following article provides additional guidance on determining the recommendation category: 
Schunemann HJ et al. Grading the quality of evidence and strength of recommendations in ATS 
guidelines and recommendations. Am J Respir Crit Care Med, 2006;174:605-14. 
17.3   Wording of Recommendations 
The language used in the recommendation should be clear and direct, indicating an unambiguous 
action. The preferred wordings for category A recommendations are “recommend,” 
“recommend against,” “should,” and “should not,” and that for category B recommendations are 
words like “may” and “suggest against.”  
18. Presenting Recommendations  
The recommendation is to be followed by the recommendation category and evidence type in 
parentheses. The key thought process behind the recommendation should be summarized.     
Example: 
Recommendation:  ACIP recommends universal vaccination of U.S. infants with three doses of 
rotavirus vaccine administered orally at ages 2, 4, and 6 months (recommendation category: A, 
evidence type: 1).  
Remarks:  Nearly every child in the U.S. is infected with rotavirus by age 5 years, resulting in 
approximately 410,000 physician visits, 205,000–272,000 emergency department visits, and 
55,000–70,000 hospitalizations each year. Vaccination reduces severe rotavirus diarrhea. The 
benefits are substantial compared to potential harms.  
Additional guidance on presenting recommendations is included in the Appraisal of Guidelines 
for Research and Evaluation (AGREE II) instrument (available at www.agreetrust.org).  
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19. Further Research Needs and Priorities 
A recommendation should summarize the available evidence as the basis of the 
recommendations. It is also useful to highlight where the available evidence regarding the effect 
of an intervention may be insufficient or inadequate. ACIP workgroups should identify research 
needs and, if appropriate, prioritize them. In formulating research needs, workgroups should be 
as specific as possible about what is needed and why. One format is EPICOT (ref: Brown P et al. 
BMJ 2006;333:804-6): 
E Evidence: What is the current state of the evidence (e.g. there is only one small 
observational study in older adults). 
P Population: What is the population of interest (e.g. older adults with chronic conditions). 
I Intervention: What are the interventions of interest (e.g. vaccination). 
C Comparison: What are the comparisons of interest (e.g. comparison to another vaccine). 
O Outcome: What are the outcomes of interest (e.g. disease, hospitalization, death, adverse 
events). 
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Appendix 1.  Example of Applying GRADE Framework 
In this example, the GRADE framework is applied in a retrospective manner to the 2006 ACIP 
recommendation for use of pentavalent rotavirus vaccine (MMWR 2006; Vol 55; RR-12:1-13). 
Studies that were available at the time of the 2006 ACIP recommendation are used. 
Background 
In the United States, rotavirus infection is responsible for approximately 410,000 physician visits, 
205,000-272,000 emergency department visits, 55,000-70,000 hospitalizations, and 20 deaths 
annually, with total annual direct and indirect costs of about $1 billion. Several candidate 
rotavirus vaccines have been assessed in field trials since 1982, which were developed from a 
variety of rotavirus strains. In 1998, ACIP recommended Rotashield (RRV-TV), a rhesus-based 
tetravalent rotavirus vaccine, for routine vaccination of U.S. infants. However, RRV-TV was 
withdrawn from the U.S. market within 1 year of its introduction because of its association with 
intussusception. In February 2006, the U.S. Food and Drug Administration (FDA) licensed a live, 
oral, human-bovine reassortant pentavalent rotavirus vaccine (RotaTeq™) as a 3-dose series for 
use among infants. The vaccine contains five reassortant rotaviruses developed from human and 




Formulating questions and choosing outcomes 
The main question is whether pentavalent rotavirus vaccine (RotaTeq™) should be administered 
routinely to all infants. There are also questions as to whether breastfed infants and infants born 
prematurely can receive the vaccine. There is also a question as to whether the vaccine can be 
co-administered with DTaP, Hib, IPV, hepatitis B, and PCV vaccines. 










Population (P):  Infants  
Intervention (I):  Rotavirus vaccine (RotaTeq) administered orally at ages 2, 4, and 6 months. 
Control (C):  No rotavirus vaccination. 
Outcomes (O):  Rotavirus diarrhea; severe rotavirus diarrhea; deaths; hospitalizations; office 

















What are the most important outcomes? 
Choose the most important outcomes for decision making. 
Consider: 
· outcomes that might be important to someone making a decision to use or not to use the 
interventions (make sure to include both benefits and harms) 
· outcomes that have been reported in systematic reviews and individual studies 
Rate the relative importance for each outcome on a 9 point scale ranging from 1 (not important) to 9 
(critical), regardless of whether data are available for the outcome.  
1 – 3 not important and not included in the Evidence Tables 
4 – 6 important but not critical for making a decision (inclusion in the Evidence Tables may depend 
on how many other important outcomes there are, as a total of up to seven important and critical 
outcomes are generally included in evidence tables) 
7 – 9 critical for making a decision and should definitely be included in the Evidence Tables. 
The same rating can be used several times (i.e. same number for more than one outcome).  







1. Rotavirus diarrhea (any severity) 6 Yes No 
2. Severe rotavirus diarrhea 9 Yes No 
3. Hospitalizations for rotavirus diarrhea 7 Yes No 
4. Office visits for rotavirus diarrhea 3 Yes No 
5. Deaths from rotavirus diarrhea 2 Yes No 
6. Intussusception 9 Yes No 
7. Other serious adverse events (fatal, life threatening, 
or require hospitalization) 
9 Yes No 
8. Mild adverse events 3 Yes No 
9. Cost-effectiveness 6 Yes No 
 
Evidence Retrieval, Assessment and Synthesis 
Included Studies: We included three phase 3 clinical trials of the efficacy, immunogenicity, and 
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safety of the pentavalent rotavirus vaccine – Study 006 rotavirus efficacy and safety trial (REST); 
Study 007 the end-expiry dose trial (end-expiry); and Study 009 immunogenicity study to 
demonstrate lot consistency of RotaTeq (lot-consistency).  
Publications from Study 006 (REST): 
· Vesikari T et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortment 
rotavirus vaccine. N Engl J Med 2006;354:23-33. 
· Goveia MG et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant 
rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007;26(12):1099-1104. 
· Goveia MG et al. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine 
based on breastfeeding frequency. Pediatr Infect Dis J 2008;27(7):656-658. 
· Rodriguez ZM et al. Concomitant use of an oral live pentavalent human-bovine reassortant 
rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr 
Infect Dis J 2007;26(3):221-227.  
· Clinical Review of New Biologics License Application STN #125122 RotaTeq. FDA, 2006. 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm 
Publications from Study 007 (end-expiry): 
· Block SL et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) 
reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007;119(1):11-18. 
· Clinical Review of New Biologics License Application STN #125122 RotaTeq. FDA, 2006. 
Publications from Study 009 (lot-consistency): 
· Clinical Review of New Biologics License Application STN #125122 RotaTeq. FDA, 2006. 
Excluded Studies: We excluded the following studies from the evidence review: 
· Phase 1 and Phase 2 clinical studies (001, 002, 003, 004, 005) that utilized a different vaccine 
formulation (fewer serotypes, not buffered, required pre-feed) than what was used in the 
phase 3 studies 006, 007, 009.  
· Trials of the tetravalent human-rhesus RotaShield vaccine (Wyeth Ayerst) that was 
withdrawn from the U.S. market after licensure in 1998 because of an association with 
intussusception. 
· Phase 1, Phase 2, and Phase 3 trials of a monovalent rotavirus vaccine containing a human 
rotavirus strain (type G1P1[8]). The monovalent rotavirus vaccine (Rotarix™), produced by 
GlaxoSmithKline, was subsequently licensed in 2008.  
· Trials of candidate rotavirus vaccines using other rotavirus strains (e.g. bovine strain, simian 
strain, lamb strain). 
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Forest Plots using Data Abstracted from Included Studies  




Question: Routine Administration of Pentavalent Rotavirus Vaccine 
Analysis 01.01.  Comparison 01 Routine administration, Outcome 01 Rotavirus diarrhea 
occurring through the first full rotavirus season after vaccination 
Per-protocol analysis (rotavirus diarrhea occurring ≥14 days after the 3rd dose) 
 
Intention-to-Treat analysis (rotavirus diarrhea occurring anytime after the 1st dose; includes 
infants who received 1 or 2 doses only) 
Analysis 01.02.  Comparison 01 Routine administration, Outcome 02 Severe rotavirus diarrhea 
occurring through the first full rotavirus season after vaccination 
 
Per-protocol analysis 
Intention-to-Treat analysis  
Analysis 01.03.  Comparison 01 Routine administration, Outcome 03 Hospitalization for 
rotavirus diarrhea through the first full rotavirus season after vaccination 
Per-protocol analysis 




Analysis 01.04.  Comparison 01 Routine administration, Outcome 05 Intussusception within 42 




Analysis 01.05.  Comparison 01 Routine administration, Outcome 06 Serious adverse events 




Table 1. Benefits: Pentavalent Rotavirus Vaccinea 
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RCT, Randomized Controlled Trial.  RV, Rotavirus. 
aPer-protocol analysis. 
 
Table 2. Safety: Pentavalent Rotavirus Vaccine 








































aNot meaningful when risk difference is not statistically significant. 
 


















diarrhea (RV)  

















for RV diarrhea  

















adverse events  







aStrength of association, dose-response, opposing plausible residual confounding or bias, publication bias. 
bEvidence type: 
  1= Randomized controlled trials (RCTs), or overwhelming evidence from observational studies. 
  2= RCTs with important limitations, or exceptionally strong evidence from observational studies. 
  3= Observational studies, or RCTs with notable limitations. 
  4= Clinical experience and observations, observational studies with important limitations, or RCTs with 
several major limitations.   
 
Table 4. Summary of Evidence: Pentavalent Rotavirus Vaccine 
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No vaccination  
Rotavirus 
diarrhea (RV)  


















for RV diarrheaa  




Intussusceptiona  RCT (3)  No difference  1 
Other serious 
adverse eventsa  
RCT (3)  No difference  1 
RCT: Randomized controlled trial.  




Moving from Evidence to Recommendation  
ð Overall evidence type 
ð Values and preferences (assume a set of values for each outcome considered) 
 
OUTCOME VALUES AND PREFERENCES 
Rotavirus diarrhea Relatively lower value 
Severe rotavirus diarrhea High value 
Hospitalization for rotavirus diarrhea High value 
Intussusception High value 
Other serious adverse events High value 
Cost effectiveness Relatively lower value 
ð Draft recommendation 





Overall evidence type  across all critical outcomes 1 
ð Judgments about the recommendation category (Category A; Category B) 
Use the table below to make a judgment. The four factors in this table will determine whether the recommendation is category A 
(recommendation for; recommendation against) or category B (individual clinical decision making).  Frequent ‘yes’ answers 
increase the likelihood of a category B recommendation.    
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Factors that can weaken a recommendation Decision  Explanation  
Lower evidence level  
[The lower the evidence level, the more likely is a 
category B recommendation.] 
□ Yes  
□ No  
Evidence level is high 
Lower net benefit or uncertainty about the balance of 
benefits versus harms and burdens  
[The smaller the net benefit and the lower certainty for 
that benefit, the more likely is a category B 
recommendation.] 
□ Yes  
□ No  
Benefits are large 
compared to potential 
harms 
Variability or uncertainty in values  
[The greater the variability in values and preferences, 
or uncertainty in values and preferences, the more 
likely is a category B recommendation.] 
□ Yes  
□ No  
Patients and providers 
would accept 
rotavirus vaccination 
Lower cost-effectiveness or uncertainty about 
whether the net benefits are worth the costs  
[The higher the costs of an intervention – that is, the 
more resources consumed – the more likely is a 
category B recommendation] 
□ Yes  
□ No  
The price per dose is 
not known. Vaccine is 
likely to be cost-saving 
from the societal 
perspective at a total 
cost of up to $156 per 
child ($42/dose).a 
aThe manufacturer subsequently set the price at $62.50/dose (in 2006 dollars); a rotavirus vaccination program 
would cost an estimated $197,190 per life-year saved. 
If consensus is not reached by discussion, the workgroup can use the table below to record their views (votes) about the 
recommendation related to a specific intervention, based on their analysis of the available evidence, the benefits and harms, 
values and preferences and economic analyses. This assessment is then mapped to the recommendation for the use, or non-use, of 
each intervention. 
 
Insert the number of votes for the recommendation in each category 
Recommend for 









Assessors’ view of 






















Recommendation  We recommend to 
“do something” 
We suggest to “do 
something” 
 We suggest to “not do 
something” 
We recommend to “not 
do something” 
Number of votes in 
workgroup 
Recommendation category Category A 
ð Final recommendation 
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We recommend routine vaccination of U.S. infants with three doses of rotavirus vaccine 





Nearly every child in the U.S. is infected with rotavirus by age 5 years, and the majority will have 
gastroenteritis, resulting in approximately 410,000 physician visits, 205,000-272,000 emergency 
department visits, and 55,000-70,000 hospitalizations each year. Randomized clinical trials show 
that vaccination reduces severe rotavirus gastroenteritis. Benefits are substantial compared to 
potential harms. 
Appendix 2.  Data Extraction Forms 
Form 1.  Information on included studies 
Author, Year: 





Number randomized or enrolled (total and per group): 
Number analyzed (total and per group): 



























Type of study (published/unpublished):
Funding source: 
Study period: 
Reported subgroup analyses: 
 
Form 2a.  Assessment of risk of bias for randomized controlled trialsa 
Author, Year: 
Name of reviewer:      Date completed: 
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The investigators describe a random 
component in the sequence 
generation process (e.g. computer 
random number generator).  
Problem if “pseudo” or “quasi” 
randomization with allocation by 






Those enrolling patients cannot 
foresee the group to which the next 
enrolled patient will be allocated 
(e.g. central allocation, sequentially 










Study participants and personnel 
are not aware of the arm to which 











Outcome assessors are not aware of 
the arm to which patients are 
allocated (assess separately for 
each outcome; outcomes may be 






Loss to follow-up; adherence to the 
intention to treat principle when 
indicatedb  
(assess separately for each 
outcome; outcomes may be 













Study reports all pre-specified or 
expected outcomes. Problem if 
reporting of some outcomes and 









extreme baseline imbalance; 
differential diagnostic activity 
 
aSee Cochrane handbook, Chapters 8 and 16 (http://www.cochrane-handbook.org/).  
bIntention-to-treat analyses may not be appropriate for adverse events or non-inferiority studies (ref: 
Cochrane handbook, Chapter 16, Section 16.2.1). 
For observational studies, see http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. 
For controlled before-after and interrupted time series, see www.epoc.cochrane.org/epoc-author-resources.  
Form 2b.  Assessment of risk of bias for cluster-randomized trialsa 
Author, Year: 
Name of reviewer:      Date completed: 
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Criteria Description Yes /No/ Unclear Quote from study 
Recruitment 
bias 
Individuals are recruited to the trial after 
the clusters have been randomized; 
knowledge of whether each cluster is an 
intervention or control cluster could affect 
the types of participants recruited. 
Strategies to minimize the possibility of 
selection bias include inclusion of all 
individuals within a cluster or recruitment 




Baseline imbalance between the 
randomized groups, in terms of either the 
clusters or the individuals. Statistical 
adjustment for baseline characteristics 
can help reduce concern about the effects 







Loss of clusters from a trial may lead to 
bias. In addition, missing outcomes for 
individuals within clusters may lead to a 
risk of bias. For example, differential 
adherence and follow-up can occur for 









The clustering effect is not taken into 
account in the analysis. Such analyses 
produce erroneously narrower standard 
errors that will result in too much weight 







In a meta-analysis including both cluster 
and individually randomized trials, or 
including cluster-randomized trials with 
different types of clusters, possible 
differences between the intervention 
effects being estimated [because of herd 
effect] need to be considered. If 
intervention effect is still demonstrated in 
individually randomized trials, a confident 
conclusion about the presence of an 
effect can be drawn. Herd effects may be 















aSee Cochrane handbook, Chapter 16.3 (http://www.cochrane-handbook.org/).  
bCampbell MK et al. CONSORT Statement: extension to cluster randomised trials. BMJ 2004;328:702-8. 
Form 3a.  Data abstraction for dichotomous outcomes 
Author, Year: 





(as stated in study)  
Intervention group Comparison group 
 
Time at follow-up 













(as stated in study)  
Intervention group Comparison group 
 
Time at follow-up 













(as stated in study)  
Intervention group Comparison group 
 
Time at follow-up 











Form 3b.  Data abstraction for continuous outcomes 
Author, Year: 









Intervention group Comparison group 
n 
Mean 
(95% CI) SDa n 
Mean 









Intervention group Comparison group 
n 
Mean 
(95% CI) SDa n 
Mean 









Intervention group Comparison group 
n 
Mean 
(95% CI) SDa n 
Mean 
(95% CI) SDa 
Notes: 
aStandard deviation (SD) = Standard error * square root of total participants in group (n). If SD is not 
reported, it can be computed from 95% CI (see Cochrane handbook, Chapter 7, Section 7.7.3). 
Form 4.  Determining evidence type 
Name of reviewer: 





(circle one for 
each criterion) 
Reasons for assessment Evidence type
a 
(Circle one per outcome) 
OUTCOME: 
Risk of bias 
No 
serious (-1) 







































  1=  Randomized controlled trials (RCTs), or overwhelming evidence from observational studies. 
  2=  RCTs with important limitations, or exceptionally strong evidence from observational studies. 
  3=  Observational studies, or RCTs with notable limitations. 
  4=  Clinical experience and observations, observational studies with important limitations, or RCTs with 
several major limitations.   
Appendix 3.  Using GRADEpro Software for Preparing Evidence Tables 
(Available at http://www.gradeworkinggroup.org/toolbox/index.htm)  
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1. Open GRADEpro.  
2. Choose New Profile in the welcome screen, enter file name, and click Save.  
3. Create profile group (usually overall topic of guidelines or main question)  
4. Create a profile (specific health care question) 
a. Choose the format of the question in the drop down box (e.g. Should 
intervention versus comparison be used for health situation?) 
b. Add information about the comparison, intervention, setting, etc. 
c. Add bibliographic information about the studies or reviews used to create the 
profile. 
 
5. Create the outcomes by naming them. 
 
6. Select an outcome. For each outcome there are 2 sections: Summary of Findings screen 
and the Quality Assessment screen.  
7. Select the Quality Assessment screen.  
a. Complete it by first confirming number and type of studies 
b. Assess the quality of evidence for the outcome. Downgrade or upgrade evidence 
according to GRADE criteria and enter footnotes when necessary.  
8. Select Summary of Findings screen.  
a. Add data about participants, estimate of effect, baseline risks, etc. 
 
9. Repeat (#7 and #8) for all outcomes in the profile.  
10. Preview GRADE evidence profile, double check presentation and edit if necessary.   
11. Export the table to a document in word, html, image, etc. 
Appendix 4.  Using Review Manager (RevMan) Software 
(Available at http://ims.cochrane.org/revman) 
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The RevMan software, developed by the Nordic Cochrane Centre, can be used to generate 
forest plots, funnel plots, and risk of bias graphs. Forest plots display results of individual 
studies in a graphical manner, and include pooled estimates of effects (e.g. summary risk ratios 
across studies) and tests for heterogeneity and I2.  Funnel plots can help assess publication bias. 
A tutorial is available on using RevMan.  After opening RevMan, click Help, select Tutorial, and 
then click Intervention Reviews. For generating the plots and graphs, the first step is to add 
studies as described in Part 3 of the tutorial.  Part 5 of the tutorial describes how forest plots 
and funnel plots can be generated, and Part 4 describes the procedure to create risk of bias 
graphs. 
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